ArticleFrontiers in public health2024
Dynamics in the prevalence and clinical manifestations of acute mountain sickness of different ascent protocols during high altitudes exposure.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Quality and reliability of health information about altitude sickness on Douyin and Bilibili: a cross-sectional study.BMC public health · 2026Article
- Qi deficiency constitution increases risk of acute mountain sickness via reduced aerobic fitness.Frontiers in public health · 2026Article
- Intelligent monitoring and individualized strategies for preventing altitude sickness during altitude training.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leisure, work, and sports activities that involve ascending to high altitudes (HA) are growing in popularity, yet they also pose the risk of developing acute mountain sickness (AMS). Despite the dynamic nature of AMS, its prevalence, clinical manifestations, and associated risks have still not to be comprehensively characterized. Methods: A total of 770 healthy males, ranging in age from 18 to 45 years, were included in this study. The subjects were divided into two cohorts: a fast ascent cohort ( Results: As diagnosed by the old LLS and new LLS, the incidence of AMS was 37.9 and 32.4% at 3650 m, respectively, which decreased to 35.7 and 32.4% after further ascending to 4,400 m in the fast ascent cohort; the incidence of AMS was 26.5 and 23.2% at 3650 m, which increased to 44.5 and 42.3% after further ascending to 4,400 m in the slow ascent cohort. Furthermore, there were noticeable disparities in the occurrence and progression of AMS-related symptoms among cohorts adhering to different ascent protocols. Specifically, fast ascent protocol posed a risk during the initial phase of the ascent, but transformed into a protective effect upon further ascent to a higher altitude. Conclusion: Ascent protocol emerged as the pivotal influence on the prevalence of AMS and associated manifestations, demonstrating a transition from a risk factor during initial ascent to a protective factor following further ascent to higher altitudes. These findings suggest an innovative strategy for high-altitude expeditions and work endeavors, emphasizing the importance of a strategic plan for ascending to higher altitudes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.